web analytics

Programmes

Discuva’s strategy addresses the current unmet urgent need to identify new drug treatment options to combat infections caused by Multidrug-resistant (MDR) Gram negative and Gram positive pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae Escherichia coli, Neisseria gonorrhoeae, Staphlococcus aureus and Enterococcus sp.

Discuva’s objectives are to progress disease-targeted antibacterial drugs from its proprietary biology platforms through to the market both with and without collaborative partners.

Discuva’s SATIN technology is applied on bacteriocidal hits identified from high-throughput phenotypic screening to identify both the molecular target(s) of each compound and all the corresponding potential resistance gene(s). The information from SATIN enables the prioritisation of compounds into chemical optimisation which ultimately have the best chance of clinical success.

The successful application of the SATIN technology is allowing Discuva to progress multiple novel compound series through chemical optimisation.

Latest Tweets from @DiscuvaLtd

Discuva Ltd @DiscuvaLtd
@DiscuvaLtd will be attending @AllianceBEAM members forum today at #ECCMID2017
Discuva Ltd @DiscuvaLtd
RT @katieforster: Deadly superbugs could be 'permanently outwitted' as scientists discover how they become resistant to antibiotics https:/…
Discuva Ltd @DiscuvaLtd
Why We Need a Culture of International Collaboration to Fight #Antibiotic Resistance https://t.co/AiV3Mp8dxq